506 related articles for article (PubMed ID: 12835706)
21. Aiming for successful vaccine-induced HIV-1-specific cytotoxic T lymphocytes.
Yang OO
AIDS; 2008 Jan; 22(3):325-31. PubMed ID: 18195558
[No Abstract] [Full Text] [Related]
22. [HIV/AIDS vaccines: heading for new vaccine approaches?].
Girard MP
Bull Soc Pathol Exot; 2008 Jun; 101(3):220-6. PubMed ID: 18681215
[TBL] [Abstract][Full Text] [Related]
23. Current and future HIV/AIDS clinical research. HIV-related therapy improving--slowly.
Henry K; Schwebke K
Minn Med; 1993 Nov; 76(11):17-23. PubMed ID: 8295612
[TBL] [Abstract][Full Text] [Related]
24. [Effect of opportunistic infections on the frequency of leukocyte subpopulations from type-1 human immunodeficiency virus infected individuals].
Ramírez Z; Cataño JC; Román A; Rugeles MT; Montoya CJ
Biomedica; 2008 Mar; 28(1):64-77. PubMed ID: 18645662
[TBL] [Abstract][Full Text] [Related]
25. Founder effects in the assessment of HIV polymorphisms and HLA allele associations.
Bhattacharya T; Daniels M; Heckerman D; Foley B; Frahm N; Kadie C; Carlson J; Yusim K; McMahon B; Gaschen B; Mallal S; Mullins JI; Nickle DC; Herbeck J; Rousseau C; Learn GH; Miura T; Brander C; Walker B; Korber B
Science; 2007 Mar; 315(5818):1583-6. PubMed ID: 17363674
[TBL] [Abstract][Full Text] [Related]
26. Cytotoxic potential of CD8+ T-cells in lymphoid follicles during HIV-1 infection.
Laman JD; van den Eertwegh AJ
AIDS; 1992 Mar; 6(3):333-5. PubMed ID: 1567581
[No Abstract] [Full Text] [Related]
27. Peptide-loaded dendritic-cell vaccination followed by treatment interruption for chronic HIV-1 infection: a phase 1 trial.
Ide F; Nakamura T; Tomizawa M; Kawana-Tachikawa A; Odawara T; Hosoya N; Iwamoto A
J Med Virol; 2006 Jun; 78(6):711-8. PubMed ID: 16628588
[TBL] [Abstract][Full Text] [Related]
28. A nonprogressive clinical course in HIV-infected individuals expressing human leukocyte antigen B57/5801 is associated with preserved CD8+ T lymphocyte responsiveness to the HW9 epitope in Nef.
Navis M; Schellens IM; van Swieten P; Borghans JA; Miedema F; Kootstra NA; van Baarle D; Schuitemaker H
J Infect Dis; 2008 Mar; 197(6):871-9. PubMed ID: 18279072
[TBL] [Abstract][Full Text] [Related]
29. Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein.
Wright PF; Mestecky J; McElrath MJ; Keefer MC; Gorse GJ; Goepfert PA; Moldoveanu Z; Schwartz D; Spearman PW; El Habib R; Spring MD; Zhu Y; Smith C; Flores J; Weinhold KJ;
J Infect Dis; 2004 Apr; 189(7):1221-31. PubMed ID: 15031791
[TBL] [Abstract][Full Text] [Related]
30. Different immunodominance of HIV-1-specific CTL epitopes among three subtypes of HLA-A*26 associated with slow progression to AIDS.
Kawashima Y; Satoh M; Oka S; Shirasaka T; Takiguchi M
Biochem Biophys Res Commun; 2008 Feb; 366(3):612-6. PubMed ID: 18035044
[TBL] [Abstract][Full Text] [Related]
31. HIV and children: the developing immune system fights back.
Feeney ME
West Indian Med J; 2004 Oct; 53(5):359-62. PubMed ID: 15675505
[TBL] [Abstract][Full Text] [Related]
32. HIV evolution in response to HLA-restricted CTL selection pressures: a population-based perspective.
Carlson JM; Brumme ZL
Microbes Infect; 2008 Apr; 10(5):455-61. PubMed ID: 18407775
[TBL] [Abstract][Full Text] [Related]
33. Destructive networks in AIDS.
Kennedy JR
Immunol Today; 1993 Dec; 14(12):615. PubMed ID: 7905741
[No Abstract] [Full Text] [Related]
34. Light shed on battle against HIV.
Check E
Nature; 2006 Aug; 442(7105):852-3. PubMed ID: 16929262
[No Abstract] [Full Text] [Related]
35. Rates of HIV immune escape and reversion: implications for vaccination.
Davenport MP; Loh L; Petravic J; Kent SJ
Trends Microbiol; 2008 Dec; 16(12):561-6. PubMed ID: 18964018
[TBL] [Abstract][Full Text] [Related]
36. Characteristics of HIV-1-specific CD8 T-cell responses and their role in loss of viremia in children chronically infected with HIV-1 undergoing highly active antiretroviral therapy.
Zhang Z; Zhao QX; Fu JL; Yao JX; He Y; Jin L; Wang FS
Chin Med J (Engl); 2006 Dec; 119(23):1949-57. PubMed ID: 17199938
[TBL] [Abstract][Full Text] [Related]
37. No vaccine against HIV yet--are we not perfectly equipped?
Singh M
Virol J; 2006 Aug; 3():60. PubMed ID: 16939652
[TBL] [Abstract][Full Text] [Related]
38. HIV immunotherapy comes of age: implications for prevention, treatment and cure.
Routy JP; Mehraj V; Cao W
Expert Rev Clin Immunol; 2016; 12(2):91-4. PubMed ID: 26629806
[TBL] [Abstract][Full Text] [Related]
39. HLA-A and -B allele expression and ability to develop anti-Gag cross-clade responses in subtype C HIV-1-infected Ethiopians.
Ferrari G; Currier JR; Harris ME; Finkelstein S; de Oliveira A; Barkhan D; Cox JH; Zeira M; Weinhold KJ; Reinsmoen N; McCutchan F; Birx DL; Osmanov S; Maayan S
Hum Immunol; 2004 Jun; 65(6):648-59. PubMed ID: 15219385
[TBL] [Abstract][Full Text] [Related]
40. Immune impairment thresholds in HIV infection.
Iwami S; Nakaoka S; Takeuchi Y; Miura Y; Miura T
Immunol Lett; 2009 Apr; 123(2):149-54. PubMed ID: 19428563
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
